Display Settings:

Format

Send to:

Choose Destination
    Ann Pharmacother. 2003 Jan;37(1):127-31.

    Management of botulism.

    Source

    Pediatric Pharmacotherapy, College of Pharmacy, Ohio State University, Columbus, OH 43210-1291, USA.

    Abstract

    OBJECTIVE:

    To provide a concise review of the presentation and treatment of botulism.

    DATA SOURCES:

    Searches of MEDLINE (1966-November 2001), tertiary references, and public and government Internet sites were conducted.

    STUDY SELECTION:

    All articles and additional references from those articles were thoroughly evaluated.

    DATA SYNTHESIS:

    Clostridium botulinum toxin blocks acetylcholine release in a dose-dependent fashion, resulting in acute symmetric diplopia, dysarthria, dysphonia, dysphagia, and possible neurologic sequelae despite the route of exposure (i.e., food-borne, wound, intestinal, inhalation). Disease secondary to genetically engineered C. botulinum may differ from that of inadvertent exposure. Present treatment is primarily supportive care, respiratory support, rapid decontamination, and antitoxin administration (i.e., trivalent, pentavalent, heptavalent antitoxin). Early initiation of antitoxin limits the extent of paralysis, but does not reverse it.

    CONCLUSIONS:

    Supportive care and the use of antitoxin have been effective in the treatment of botulism from food-borne, intestinal, and wound exposure. However, the effectiveness of antitoxin in the treatment of inhaled C. botulinum has not been proven.

    PMID:
    12503947
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk